This study aimed to determine features of patients switching between these drugs. Inefficacy or side effects may cause switching from one biologic agent to another. Patients who were in clinical remission were asked to switch from RI to BI using the same therapeutic perspective.

Methods: One hundred and nine consecutive unselected AS patients were investigated. All, followed-up at predefined times receiving RI (5mg/kg/8 weeks) and naïve to other biologics. Patients who were in clinical remission were asked to switch from RI to BI using the same therapeutic perspective. Nine patients switched to RI and 10 patients to BI were included (n=20). Disease activity was measured using the Bath Ankylosing Spondylitis activity index (BASDAI), and the Ankylosing Spondylitis disease activity score (ASDAS), using the C-reactive protein. Remission was defined if patients achieved BASDAI <4 and ASDAS <1.3.

Results: Twenty-one patients were excluded, nine because had no clinical activity score (ASDAS) at 3 months of treatment, all patients in both groups remained in clinical remission (BASDAI <4 and ASDAS <1.3). During follow-up, five patients from the switched group and three from the maintenance group discontinued the study.

Conclusion: BI is equivalent to RI in maintaining AS in clinical remission for at least 18 months.

Acknowledgement: We have no acknowledgement for this abstract.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2019-eular.4007

REFERENCES:
[1] Dagfinrud, et al. Arthritis Care Res. 2011;63(4):597-603.
[2] Niedermann, et al. Arthritis Care Res. 2018. Doi: -10.1002/acr.23705

Acknowledgement: The authors thank the Dutch Arthritis Society for funding this study and for thinking along from the patients’ perspective. They also thank all participants, coordinators, boards and guiding therapists from the four included SGE regions.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2019-eular.3718

MAINTAINED CLINICAL REMISSION IN ANKYLOSING SPONDYLITIS PATIENTS SWITCHED FROM REFERENCE INFILXIMABOTO ITS BIOSIMILAR. AN 18-MONTH COMPARATIVE OPEN-LABEL STUDY

Evripidis Katsanosn1, Eletherios Pelechans2, Paraskevi Voulgan2, Alexandros Drososs1. We have no working group for this abstract. 1 Rheumatology Clinic, University of Ioannina, Ioannina, Greece, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece; 2 Rheumatology Clinic, University of Ioannina, Ioannina, Greece, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece

Background: switching from reference infliximab (RI) to biosimilar infliximab (BI) had no detrimental effects on efficacy and safety compared to continued RI. However, long-term follow-up data is missing.

Objectives: the aim of this study was to evaluate if BI is equivalent to RI to maintain patients with Ankylosing Spondylitis (AS) in clinical remission, in a long-term fashion.

Methods: one hundred and nine consecutive unselected AS patients were investigated. All, followed-up at predefined times receiving RI (5mg/kg/8 weeks) and naïve to other biologics. Patients who were in clinical remission were asked to switch from RI to BI using the same therapeutic perspective. Nine patients switched to RI and 10 patients to BI were included (n=20). Disease activity was measured using the Bath Ankylosing Spondylitis activity index (BASDAI), and the Ankylosing Spondylitis disease activity score (ASDAS), using the C-reactive protein. Remission was defined if patients achieved BASDAI <4 and ASDAS <1.3.

Results: Twenty-one patients were excluded, nine because had no clinical activity score (ASDAS) at 3 months of treatment, all patients in both groups remained in clinical remission (BASDAI <4 and ASDAS <1.3). During follow-up, five patients from the switched group and three from the maintenance group discontinued the study.

Conclusion: BI is equivalent to RI in maintaining AS in clinical remission for at least 18 months.

Acknowledgement: We have no acknowledgement for this abstract.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2019-eular.4007

SWITCHING RATE OF ANTI-TNF AGENTS IN SPONDYLOARTHRITIS PATIENTS: TREASURE – REAL LIFE DATA

Umut Kalyoncu, Sedat Kiraz, Abdulasmset Erden, Orhan Küçükşahin, Tümicin Kaşığıoğlu, Ediz Daikiliç, Cemal Bes, Nilüfer Alpay Kanez, Hakan Emmunligi, Pamar Atağündüz, Belkis Nihan Coğrub, Burcu Yalız, Süleyman Serdar Koca, Muhammet Cinar, Aşgın Ataş, Servet Akar, Onay Gercik, Duygu Erüzlu, Veli Yazda, Gezmi İlhan, Servet Akar, Onay Gercik, Umut Kalyoncu, Abdulsamet Erden, Orhan Küçükşahin, Hakan Emmunligi, Pamar Atağündüz, Belkis Nihan Coğrub, Burcu Yalız, Süleyman Serdar Koca, Muhammet Cinar, Aşgın Ataş, Servet Akar, Onay Gercik, Duygu Erüzlu, Veli Yazda, Gezmi İlhan, Servet Akar, Onay Gercik.

Background: In spondyloarthritis (SpA), biologic DMARDs are important treatment options in resistant patients. Inefficacy or side effects may cause switching between subcutaneous anti-TNF agents is generally less than switching from infliximab to another biologic agent.

Objectives: This study aimed to determine features of patients switching from one biologic agent to another in SpA treatment and to investigate associated reasons.

Methods: This multicenter, prospective observational cohort study used the TReasure database in which web-based registration of rheumatoid arthritis and SpA patients are being performed in 15 centers across different regions of Turkey. In this study, data of SpA patients switching from one biologic agent to another were analyzed. Demographic and clinical data, follow-up duration, time to switch, and reasons for switching were retrieved from the database. Kaplan-Meier analysis was performed to show drug retention rates and Cox regression analysis was performed to investigate the factors affecting switching.

Results: Of the included 3198 SpA patients, 1165 (37.1%) switched to another biologic agent (switched group) and 1937 (62.9%) continued to receive their current therapies (continued group). The median follow-up duration of all patients was 3.8 years and the median time to switch was 1.0 years (0-13.4 years). According to the distribution of comorbidities, the rates of patients having diabetes mellitus, hyperlipidemia, asthma, gastrointestinal bleeding, and cancer were significantly higher in the switched group than those of in the continued group (8.4% vs. 5.8%, p=0.006; 14.5% vs. 9.2%, p=0.001; 15.6% vs. 6.2%, p<0.001; 3.2% vs. 1.8%, p=0.018; and 1.0% vs. 0.3%, p=0.019; respectively). Features of the patients are presented in Table 1. Cox regression analysis revealed that female gender HR 1.47 (95% CI 1.24-1.75), p<0.001, disease duration HR 1.016 (95% CI 1.00-1.03), p=0.009, and BASDAI score HR 1.095 (95% CI 1.05-1.14), p<0.001 were the significant increasing factors for switching from one biologic agent to another.

In the switched group (n=1165), the main reasons for switching were secondary inefficacy (n=351), primary inefficacy (n=328), and side effects (n=287) followed by primary or secondary unknown inefficacy (n=57), physician’s request (n=45), patient’s demand (n=36), willing to be pregnant (n=9), other (n=37), and unknown (n=70).

Conclusion: In SpA patients, switching was frequent between anti-TNF agents and the median time to first switch was 1 year. Female gender, short disease duration, and lower BASDAI score were found to be the significant factors affecting switching from the anti-TNF agent used at first. The main reasons for this switching were primary (29.0%) and secondary (31.0%) inefficacy followed by side effects (23.6%). Switching between subcutaneous anti-TNF agents is generally less than switching from infliximab to another biologic agent.

Disclosure of Interests: Umut Kalyoncu Grant/research support from: MSD, Roche, UCB, Novartis and Pfizer. Consultant for: MSD, Abbvie, Roche, UCB, Novartis, Pfizer and Abdi Ibrahim, Speakers bureau: MSD, Abbvie, Roche, UCB, Novartis, Pfizer and Abdi Ibrahim. Orhan Küçükşahin: None declared.

Disclosure of Interests: None declared. Abdulsamet Erden: None declared, Orhan Küçükşahin: None declared, Tümicin Kaşığıoğlu: None declared, Ediz Daikiliç Grant/ research support from: MSD and Abbvie, Consultant for: MSD, Abbvie, Roche, UCB, Pfizer and Novartis, Cemal Bes: None declared, Nilüfer Alpay Kanez: None declared, Hakan Emmunligi Grant/research support from: MSD.

Figure 1. Kaplan-Meier curve for drug retention rates in the switched group.
Roche, Pfizer, Abbvie, Consultant for: Novartis, Roche, Speakers bureau: MSD, Roche, Pfizer, Abbvie, Celtrion, Novartis, Pamir Atagündüz: None declared, Bekus Nihan Çoğun: None declared, Burcu Yarız: None declared, Süleyman Serdar Koca: None declared, Muhammet Çınar: None declared, Aşıkon Ateş: None declared, Servet Akar Grant/research support from: from MSD, Abbvie, Roche, UCB, Novartis, Pfizer, Amgen, Consultant for: MSD, Abbvie, Roche, UCB, Novartis, Pfizer, Amgen, Speakers bureau: Pfizer, Onay Gerick: None declared, Duygu Erszlüö: None declared, Veli Yalıçez: None declared, Gezimiz Kimyon: None declared, Muge Aydin: None declared, Rüdan Mercan: None declared, Burak Ozu: None declared, Nazife Süle Yasar Bilge: None declared, Zeynel Abidin Akar: None declared, Omer Karadag: None declared, Ayse Bahar Kelesoglu declared, Süleyman Serdar Koca: None declared, Muhammet Çınar: None declared, Hans-Peter Tony Consultant for: Eli Lilly and Company, Gerd Greger: None declared, Annika Boas Shareholder of: Abbvie, Harald Burkhardt Grant/research support from: BMS, Pfizer, Janssen, Consultant for: Abbvie, Pfizer, Roche, Chugai, Bristol-Myers Squibb, Celgene, MSD, Novartis, Roche, Sanofi Pasteur, Speakers bureau: Actelion, Basel, Bristol-Myers Squibb, MSD, Novartis, Roche, Chugai, Pfizer, Novartis, Pfizer, Roche, UCB, Eva Christina Schwanek: None declared, Holger Grann: None declared, Hans-Peter Tony Consultant for: Eli Lilly and Company, Speakers bureau: Eli Lilly and Company, Gerd Greger: None declared, Annika Boas Shareholder of: Abbvie, Harald Burkhardt Grant/research support from: BMS, Pfizer, Janssen, Consultant for: Abbvie, Pfizer, Roche, Chugai, Prophylx, Bioline, Novartis, Consultant for: Abbvie, Pfizer, Roche, Chugai, UCB, Bristol-Myers Squibb, Celgene, MSD, Novartis, Biotest, Janssen, Genzyme, Eli Lilly, Speakers bureau: Ad board: Abbvie, Pfizer, Roche, Chugai, UCB, Bristol-Myers Squibb, Celgene, Novartis, Biotest, Janssen, Genzyme, Eli Lilly DOI: 10.1136/annrheumdis-2019-eular.5285

FR10396
CHARACTERIZATION OF PATIENTS WITH INF LAMMATORY BOWEL DISEASE IN THE ANK YLOSING SPONDYLITIS COHORT PRIOR TO AND DURING ADALIMUMAB TREATMENT: DATA FROM A LARGE GERMAN NON-INTERVENTIONAL STUDY

Michaels Kahlrm 1,2, Marc Schmalzing 3, Eva Christina Schwanek 3, Helgi Grann 3, Hans-Peter Tony 4, Gerd Greger 4, Annika Boas 5, Harald Burkhardt 1,2, Frank Behrens 1,2,4, 1Rheumatology Department, University Hospital Goethe-University, Frankfurt, Germany; 2Frauenheime IME Branch for Translational Medicine and Pharmacology, Frankfurt, Germany; 3Department of Rheumatology and Immunology, University Hospital, Würzburg, Germany; 4FKM, München, Germany; 5AbbVie, Westbaden, Germany; 6Centre of Innovative Diagnostics and Therapeutics, Rheumatology/Immunology at Goethe-University, Frankfurt, Germany

Background: Spondyloarthritides (SpA) are characterized by different disease manifestations such as arthritis, enthesitis, dactylitis and associated to concomitant diseases like Inflammatory bowel diseases (IBD) including ulcerative colitis (UC) and crohn’s disease (CD). IBD might have a specific role to SpA due to common pathophysiological pathways. Characteristics of the rheumatic disease and response to treatment may differ within the phenotypic manifestation and with and without associated diseases. Adalimumab (ADA) is a monoclonal antibody inhibiting TNF alpha which has demonstrated efficacy in both, nraxSpA and ankylosing spondylitis (AS) as well as for UC and CD.

Objectives: To evaluate patient baseline characteristics prior to and treatment response on different disease manifestations in a cohort of AS patients with IBD compared to an AS without IBD during ADA treatment.

Methods: Data from a large German multicenter prospective observational non-interventional study (n=3,756) of patients with active AS who initiated ADA therapy during routine clinical care were analyzed with focus on specific patient groups: (1) patients with AS and IBD at baseline (n=166) and (2) patients with AS without IBD at baseline (n= 3,590). Patient characteristics and prevalence of concomitant IBD over 24 months were analyzed.

Results: Of 3,756 patients in the main analysis set, 166 (4.4%) were identified to suffer from concomitant IBD at baseline. Baseline characteristics showed differences in gender distribution, proportion of patients with enthesitis, psoriasis and uveitis showing a higher proportion of each for the IBD group (Table). After 24 months of ADA treatment, both patient groups had similar decreases for BASDAI, BASMI, BASFI and dactylitis improvement. The IBD group had a faster decrease in BASDAI at M6 to its maximum improvement (delta of 1.9) which was kept stable until M24. For clearance of enthesitis, ADA had its largest therapeutic effect at M6 in the IBD group (clearance in 15.3% of the patients) while the AS without IBD group had the largest decrease of 10.2% at month 24. Resolving of uveitis with ADA therapy was more often seen in the IBD group compared to the AS without IBD (delta of 6% at M12 compared to delta of 2.6% at M12, respectively). The prevalence of IBD in AS in patients treated with ADA changed from 4.4% at baseline to 1.9% at M24.

Conclusion: Within the cohort of AS, patients’ characteristics of manifestations are associated to different treatment responses: Patients identified to have IBD at baseline respond better for resolving of enthesitis and show a faster response in BASDAI compared to the group without IBD. Overall a significant reduction in the prevalence of clinically relevant IBD was seen earliest at month 3 after ADA initiation.

Table. Baseline characteristics of patients with IBD within the documented AS cohort treated with ADA

FR10397
EFFICACY AND SAFETY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL: RESULTS FROM THE 48-WEEK RUN-IN PART OF C-OPTIMISE

Robert B.M. Landewill 1, Desirée van der Heijde 2, Maxime Dougdas 3, Xenonon Paralikatos 2, Filip van den Bosch 4, Karl Gaffney 4, Natasha de Peyrecave 4, Lars Bauer 5, Bengt Hoepken 5, Karen Thomas 5, Lianna S. Genlsler 6.

1Rheumatology Department, University Hospital Goethe-University, Frankfurt, Germany; 2Fraunhofer IME Branch for Translational Medicine and Pharmacology, Frankfurt, Germany; 3Department of Rheumatology and Immunology, University Hospital, Würzburg, Germany; 4FKM, München, Germany; 5AbbVie, Westbaden, Germany; 6Centre of Innovative Diagnostics and Therapeutics, Rheumatology/Immunology at Goethe-University, Frankfurt, Germany

Background: C-OPTIMISE is the first trial to evaluate whether certolizumab pegol (CZP) can be reduced/discontinued in patients with radiographic(r)-axSpA/ankylosing spondylitis (AS) and non-radiographic(nr)-axSpA achieving sustained remission after 48 weeks’ (wks) treatment.

Objectives: Here, we report interim efficacy and safety data for both subpopulations from the ongoing trial.

Methods: Up to Wk48. C-OPTIMISE (NCT02505542) was open-label (Part A), followed by 48-wk parallel-group, double-blind, placebo-controlled treatment (full dose and half dose) to Wk66 (Part B). Patients with adult-onset axSpA of <5 years’ duration, fulfilling Assessment of SpondyloArthritis international Society (ASAS) classification criteria, were recruited. Part A: patients received CZP 400mg at Wks0/2/4, then 200mg every 2 weeks [GW2]; patients achieving sustained remission (Ankylosing Spondylitis Disease Activity Score [ASDAS]<=1.3 at Wk32 and <2.1 at Wk36 [or vice versa], and <1.3 at Wk48) were eligible for Part B (secondary outcome). Primary outcome (not reported); percentage of patients in Part B not experiencing a flare. Missing values were imputed using non-responder imputation (NRI) and last observation carried forward (LOCF).

Results: Part A: Of 736 patients (Table A), 43.9% achieved sustained remission (r-axSpA/AS: 42.8%; nr-axSpA: 45.3%; NRI). At baseline, 98.5% patients had high/very high disease activity (ASDAS>2.1) at Wk48,